title: Multicentre, controlled, randomised and blinded field study comparing efficacy of suxibuzone and phenylbutazone in lame horses.
abstract: BACKGROUND
  In horses, it has been demonstrated that suxibuzone (SBZ) has a lower gastric ulcerogenic effect than phenylbutazone (PBZ). However, no field trials have been reported comparing the efficacy of the drugs in alleviating lameness.
  
  
  OBJECTIVE
  To compare the therapeutic effect of SBZ to that of PBZ when administered orally in lame horses. Acceptability of both products was also compared.
  
  
  METHODS
  Lame horses (n = 155) were used in a multicentre, controlled, randomised and double-blinded clinical trial. Horses were treated orally with either SBZ or PBZ at equivalent therapeutic dosages. PBZ was given to 79 horses at a dose of 4.4 mg/kg bwt/12 h for 2 days, followed by 2.2 mg/kg bwt/12 h for 6 days. SBZ was given to 76 horses at 6.6 mg/kg bwt/12 h for 2 days, followed by 3.3 mg/kg bwt/ 12 h for 6 days. Efficacy of treatments was evaluated by clinicians in equine practices according to lameness progression throughout the study. Product ingestion was checked daily to evaluate product acceptability.
  
  
  RESULTS
  Although SBZ showed a statistically significant tendency to have a better efficacy than PBZ (Odds ratio = 2.7; P = 0.016), significance dissipated once the analysis was adjusted for some imbalanced baseline covariates, confirming that they were actually related to the apparent advantage of SBZ over PBZ. Product acceptability was significantly higher in the SBZ group than in the PBZ group (96.1% vs. 77.2%; P = 0.001).
  
  
  CONCLUSIONS
  SBZ and PBZ did not show significant differences in alleviating lameness in horses. However, SBZ had better product acceptability when administered orally with some food.
  
  
  CONCLUSIONS
  SBZ is a good therapeutic alternative to PBZ in horses since there is no significant difference in alleviating lameness between the 2 therapies.
authors.affiliation: Department of Research and Development, ESTEVE veterinaria, Laboratorios ESTEVE, Barcelona, Spain.
authors.forename: D
authors.initials: D
authors.lastname: Sabaté
authors.forename: J
authors.initials: J
authors.lastname: Homedes
authors.forename: M
authors.initials: M
authors.lastname: Salichs
authors.forename: M
authors.initials: M
authors.lastname: Sust
authors.forename: L
authors.initials: L
authors.lastname: Monreal
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses; D007794:Lameness, Animal / Q000188:drug therapy*; D008297:Male; D010653:Phenylbutazone / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; C003371:suxibuzone; D010653:Phenylbutazone